Advocacy intelligence hub — real-time data for patient organizations
National Institute of Allergy and Infectious Diseases (NIAID) — PHASE1
University of Tennessee Graduate School of Medicine — PHASE2
Assistance Publique - Hôpitaux de Paris
Huazhong University of Science and Technology — NA
Assiut University
Children's Hospital Medical Center, Cincinnati — PHASE2
University Hospital Heidelberg
Mayo Clinic — NA
Hivid: FDA approved
Combination therapy with zidovudine is indicated for the treatment of adult patients with advanced HIV infection (CD4 count < 300) who have demonstrated malignant clinical or immunologic deterioration.
Retrovir: FDA approved
Management of certain adult patients with symptomatic HIV infection (AIDS and advanced ARC) who have a history of cytologically confirmed Pneumocytis carinii pneumonia (PCP) or an absolute CD4 (T4 helper/induccer) lymphocyte count of less than 200/mm in the peripheral blood before therapy is begun
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance2
Hivid
(Zalcitabine)Orphan drugHoffmann-La Roche, Inc.
Retrovir
(zidovudine)Orphan drugGlaxo Wellcome Inc.
Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]
12.1 Mechanism of Action Zidovudine is an antiretroviral agent [see Microbiology ( 12.4 )] .
Nelson Leung, MD, M.D
Mayo Clinic
📍 ROCHESTER, MN
Yasar Caliskan, MD, MD
Division of Nephrology, Department of Internal Medicine, Istanbul Faculty of Medicine
📍 NASHVILLE, TN
Tomasz Sablinski, MD, PhD
CT Development America, Inc.
John L Berk, M.D., D.D.S
Boston University
📍 CASTRO VALLEY, CA
Tommi Pätilä, Docent
Chief Medical Officer
Hugo A Katus
Heidelberg University